Larvol Delta - P2a-EfficacySafety-of-ALTB268-in-Subjects-wModerately-to-Severely-Active-UC-Refractory-to-Biologics

leiolizumab (ALTB-268) - AltruBio

http://clinicaltrials.gov/ct2/show/NCT06109441

Oct 31, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next